Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections
- 1 September 2016
- journal article
- research article
- Published by Elsevier BV in Gastroenterology
- Vol. 151 (3), 448-456.e1
- https://doi.org/10.1053/j.gastro.2016.05.021
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Direct‐acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN‐free treatment and future perspectivesLiver International, 2016
- Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 InfectionThe New England Journal of Medicine, 2015
- Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated CirrhosisThe New England Journal of Medicine, 2015
- Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 InfectionThe New England Journal of Medicine, 2015
- The New Era of Interferon-Free Treatment of Chronic Hepatitis CVisceral Medicine, 2015
- A phase 1, randomized, dose‐ranging study of GS‐5816, a once‐daily NS5A inhibitor, in patients with genotype 1–4 hepatitis C virusJournal of Viral Hepatitis, 2015
- P0899 : Preclinical profile of the pan-genotypic HCV NS3/4A protease inhibitor GS-9857Journal of Hepatology, 2015
- P0861 : Evaluation of the pan-genotypic HCV NS3/4A protease inhibitor GS-9857 in healthy volunteersJournal of Hepatology, 2015
- Update on hepatitis C: Direct-acting antiviralsWorld Journal of Hepatology, 2015
- Treatment of Hepatitis CJAMA, 2014